Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types-Reference-Cited by-同舟云学术

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types

Published:2023-04-20 Issue:2 Volume:8 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Nolan Katrina M.¹^ORCID,Seaton Brent²,Antonello Joseph¹,Zhang Yuhua¹,Cook Lauren¹,Delfino Krystyn¹,Rubinstein Leonard J.¹,Cheon Kyeongmi¹,Group Thomas¹,Luxembourg Alain¹,Dubey Sheri¹

Affiliation:

1. Merck & Co., Inc., Rahway, New Jersey, USA

2. Q2 Solutions Vaccines, San Juan Capistrano, California, USA

Abstract

Assay modernization is a key aspect of vaccine life cycle management. Thus, new, reoptimized versions of two 9vHPV immunoassays have been developed and validated for use in ongoing and future HPV vaccine clinical trials.

Funder

Merck Sharp & Dohme LLC

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/msphere.00962-21

Reference33 articles.

1. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

2. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine

3. 9-Valent human papillomavirus vaccine: a review of the clinical development program

4. Xiamen Innovax Biotech CO. LTD. 2019. NMPA announce the approval to bivalent HPV vaccine type 16 & 18 (Cecolin). Available from http://www.innovax.cn/en/news_view.aspx?newsCateid=56&cateid=56&NewsId=976.

5. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine;Pediatrics;2024-07-09

2. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety;Pediatrics;2023-09-05

3. Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine;Journal of Medical Virology;2023-08